stavudine has been researched along with Atrophy in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Azu, OO; Chuturgoon, A; Masia, T; Naidu, EC; Naidu, JS; Nzemande, NF; Singh, S | 1 |
Bratt, GA; Eriksson, LE; Nilsson Schönnesson, L | 1 |
Borgonovo, S; Brambilla, P; Cafarelli, L; Giacomet, V; Mora, S; Viganò, A; Zamproni, I; Zuccotti, G | 1 |
1 trial(s) available for stavudine and Atrophy
Article | Year |
---|---|
Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atrophy; Benzoxazines; Body Composition; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Female; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Italy; Male; Organophosphonates; Prospective Studies; Protease Inhibitors; Stavudine; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2007 |
2 other study(ies) available for stavudine and Atrophy
Article | Year |
---|---|
Testicular histomorphologic and stereological alterations following short-term treatment with highly active antiretroviral drugs (HAART) in an experimental animal model.
Topics: alpha-Tocopherol; Animals; Anti-HIV Agents; Antioxidants; Antiretroviral Therapy, Highly Active; Ascorbic Acid; Atrophy; Lamivudine; Male; Models, Animal; Necrosis; Nevirapine; Random Allocation; Rats; Rats, Sprague-Dawley; Seminiferous Tubules; Stavudine | 2014 |
Lipoatrophy of the footpad in HIV-treated patients is associated with increased PAI-1.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Atrophy; Cardiovascular Diseases; Cross-Sectional Studies; Didanosine; Foot; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prevalence; Risk Factors; Stavudine | 2011 |